BioNTech SE 4

CEO Ugur Sahin sold 20,500 BioNTech SE ordinary shares for about $1.97 million under a Rule 10b5-1 trading plan.

On September 10, 2026, BioNTech SE Chief Executive Officer Ugur Sahin sold 20,500 ordinary shares of BioNTech SE at an average price of approximately $96.31 per share, for total proceeds of about $1.97 million, in a transaction coded as a sale (S) under a Rule 10b5-1 trading plan established on June 3, 2026. Following the transaction, he directly owned 688,209 ordinary shares, and indirectly beneficially owned an additional 39,218,111 ordinary shares through Medine GmbH, of which he is the sole shareholder; 106,721 of those indirect shares are held in trust where Medine GmbH retains voting but not dispositive power. The transaction modestly reduced his directly held position while leaving his substantial indirect beneficial ownership through Medine GmbH largely unchanged.

Filing Facts

CIK

1776985

Ticker

BNTX

Form

4

Source Type

fda

Accession

0002123975-26-000013

Alert Tier

7